Assembly Biosciences (STU:V7B) E10: €-26.64 (As of Mar. 2026)


STU:V7B Assembly Biosciences Inc STU:V7B
31 GF Score
Price €24.00
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences E10?

Assembly Biosciences STU:V7B -1.23% 31 E10 is €-26.64 as of Mar. 2026. GuruFocus rates STU:V7B with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Assembly Biosciences's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.467. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-26.64 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 9.30% per year. During the past 5 years, the average E10 Growth Rate was 14.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Assembly Biosciences was 39.20% per year. The lowest was 9.30% per year. And the median was 19.00% per year.

As of today (2026-07-11), Assembly Biosciences's current stock price is €24.00. Assembly Biosciences's E10 for the quarter that ended in Mar. 2026 was €-26.64. Assembly Biosciences's Shiller PE Ratio of today is .


Assembly Biosciences  (STU:V7B) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Assembly Biosciences E10 Related Terms


Assembly Biosciences E10 Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences E10 Chart

Assembly Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.36 -38.52 -34.21 -29.70 -25.27

Assembly Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.11 -27.40 -25.56 -25.27 -26.64

STU:V7B vs CTNM, PRTA, RGNX: E10 Comparison

For the Biotechnology subindustry, Assembly Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Shiller PE Ratio falls into.


STU:V7B
31GF Score
Assembly Biosciences Inc STU:V7B
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Assembly Biosciences's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.467/330.2130*330.2130
=-0.467

Current CPI (Mar. 2026) = 330.2130.

Assembly Biosciences Quarterly Data

per share eps CPI Adj_EPS
201606 -6.301 241.018 -8.633
201609 -7.164 241.428 -9.799
201612 -7.622 241.432 -10.425
201703 -9.088 243.801 -12.309
201706 -8.330 244.955 -11.229
201709 -7.148 246.819 -9.563
201712 -1.115 246.524 -1.494
201803 -7.786 249.554 -10.303
201806 -13.354 251.989 -17.499
201809 -8.947 252.439 -11.703
201812 -10.864 251.233 -14.279
201903 -11.151 254.202 -14.485
201906 -7.646 256.143 -9.857
201909 -10.460 256.759 -13.452
201912 -10.584 256.974 -13.600
202003 -8.254 258.115 -10.560
202006 2.025 257.797 2.594
202009 -0.917 260.280 -1.163
202012 -10.949 260.474 -13.880
202103 -6.955 264.877 -8.671
202106 -5.478 271.696 -6.658
202109 -4.182 274.310 -5.034
202112 -14.549 278.802 -17.232
202203 -5.230 287.504 -6.007
202206 -5.790 296.311 -6.452
202209 -5.818 296.808 -6.473
202212 -5.249 296.797 -5.840
202303 -4.166 301.836 -4.558
202306 -3.581 305.109 -3.876
202309 -3.083 307.789 -3.308
202312 -1.623 306.746 -1.747
202403 -1.527 312.332 -1.614
202406 -1.839 314.175 -1.933
202409 -1.361 315.301 -1.425
202412 -1.499 315.605 -1.568
202503 -1.082 319.799 -1.117
202506 -1.153 322.561 -1.180
202509 -0.613 324.800 -0.623
202512 1.190 324.054 1.213
202603 -0.467 330.213 -0.467

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-26.64 mean?
Assembly Biosciences (STU:V7B) has a E10 of €-26.64 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Assembly Biosciences and its competitors.
Is Assembly Biosciences' E10 too high?
Assembly Biosciences' current E10 is €-26.64. Overall, Assembly Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' E10 compare to CTNM and PRTA?
Assembly Biosciences' E10 of €-26.64 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current E10 is €-26.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (STU:V7B) has a current E10 of €-26.64. The current E10 is €-26.64. Assembly Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Assembly Biosciences (STU:V7B), the current E10 is €-26.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Assembly Biosciences Business Description

Other Exchanges ASMB:USA
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score

Get the complete analysis for STU:V7B

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.00
Price